Premium
Circulating lipidomic alterations in obese and non‐obese subjects with non‐alcoholic fatty liver disease
Author(s) -
Jung Youngae,
Lee Min Kyung,
Puri Puneet,
Koo Bo Kyung,
Joo Sae Kyung,
Jang Seo Young,
Lee Dong Hyeon,
Jung Yong Jin,
Kim Byeong Gwan,
Lee Kook Lae,
Park TaeSik,
Kang KiTae,
Ryu Do Hyun,
Kang Sang Won,
Kim Donghee,
Oh Sohee,
Kim Won,
Hwang GeumSook
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16066
Subject(s) - medicine , fatty liver , steatohepatitis , lipidomics , insulin resistance , body mass index , endocrinology , obesity , metabolic syndrome , gastroenterology , disease , bioinformatics , biology
Summary Background Non‐alcoholic fatty liver disease (NAFLD) affects obese and non‐obese individuals. However, mechanisms underlying non‐obese non‐alcoholic steatohepatitis (NASH) remain unclear. Aims To attempt to identify metabolic perturbations associated with non‐obese and obese NAFLD using a lipidomics approach. Methods A cross‐sectional analysis of 361 subjects with biopsy‐proven NAFLD (157 NAFL and 138 NASH) and healthy controls (n = 66) was performed. Individuals were categorised as obese or non‐obese based on the Asian cut‐off for body mass index. Circulating lipidomic profiling of sera was performed based on the histological severity of NAFLD. Circulating lipidomic alterations were validated with an independent validation set (154 NAFLD subjects [93 NAFL and 61 NASH] and 21 healthy controls). Results Saturated sphingomyelin (SM) species were significantly associated with visceral adiposity in non‐obese NAFLD (SM d38:0; P < 0.001) but not in obese NAFLD. Additionally, SM levels were significantly associated with systemic and adipose tissue insulin resistance (SM d38:0; P = 0.002 and <0.001, respectively). Five potential lipid metabolites for non‐obese subjects and seven potential lipids for obese subjects were selected to predict NAFLD and NASH. These lipid combinations showed good diagnostic performance for non‐obese (area under the curve [AUC] for NAFLD/NASH = 0.916/0.813) and obese (AUC for NAFLD/NASH = 0.967/0.812) subjects. Moreover, distinctly altered patterns of diacylglycerol (DAG), triacylglycerol (TAG) and SM levels were confirmed in the validation set depending on the histological severity of NAFLD. Conclusion Non‐obese and obese NAFLD subjects exhibit unique circulating lipidomic signatures, including DAGs, TAGs and SMs. These lipid combinations may be useful biomarkers for non‐obese and obese NAFLD patients.